BRPI0815567A2 - Anticorpos híbridos antialfa v-integrina projetados - Google Patents

Anticorpos híbridos antialfa v-integrina projetados

Info

Publication number: BRPI0815567A2
Authority: BR; Brazil
Prior art keywords: antialfa; integrine; hybrid antibodies; antibodies designed; designed
Prior art date: 2007-07-17

Application number

BRPI0815567-4A2A

Other languages

English (en)

Inventor

Simon Goodman

Diane Hahn

Francesc Mitjans

Jaume Adan

Kin-Ming Lo

Original Assignee

Merck Patent Gessellschaft Mit Beschraenkter Haftung

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-07-17

Filing date

2008-07-17

Publication date

2015-02-18

2008-07-17 Application filed by Merck Patent Gessellschaft Mit Beschraenkter Haftung filed Critical Merck Patent Gessellschaft Mit Beschraenkter Haftung

2015-02-18 Publication of BRPI0815567A2 publication Critical patent/BRPI0815567A2/pt

2019-06-04 Publication of BRPI0815567B1 publication Critical patent/BRPI0815567B1/pt

2021-05-25 Publication of BRPI0815567B8 publication Critical patent/BRPI0815567B8/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Mycology (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Endocrinology (AREA)
Oncology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

BRPI0815567A 2007-07-17 2008-07-17 anticorpos híbridos anti-alfa v-integrina projetados, proteína de fusão e composição farmacêutica BRPI0815567B8 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP07013964.7		2007-07-17
EP07013964		2007-07-17
PCT/EP2008/005852 WO2009010290A2 (en)	2007-07-17	2008-07-17	Engineered anti-alpha v- integrin hybrid antibodies

Publications (3)

Publication Number	Publication Date
BRPI0815567A2 true BRPI0815567A2 (pt)	2015-02-18
BRPI0815567B1 BRPI0815567B1 (pt)	2019-06-04
BRPI0815567B8 BRPI0815567B8 (pt)	2021-05-25

Family

ID=40029330

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0815567A BRPI0815567B8 (pt)	2007-07-17	2008-07-17	anticorpos híbridos anti-alfa v-integrina projetados, proteína de fusão e composição farmacêutica

Country Status (19)

Country	Link
US (1)	US8562986B2 (pt)
EP (2)	EP2167128B1 (pt)
JP (1)	JP5341889B2 (pt)
KR (1)	KR101559596B1 (pt)
CN (1)	CN101687039B (pt)
AU (1)	AU2008277907B2 (pt)
BR (1)	BRPI0815567B8 (pt)
CA (1)	CA2693863C (pt)
CY (1)	CY1113493T1 (pt)
DK (1)	DK2167128T3 (pt)
EA (1)	EA019485B1 (pt)
ES (1)	ES2395799T3 (pt)
HR (1)	HRP20120949T1 (pt)
IL (1)	IL203269A (pt)
PL (1)	PL2167128T3 (pt)
PT (1)	PT2167128E (pt)
SI (1)	SI2167128T1 (pt)
WO (1)	WO2009010290A2 (pt)
ZA (1)	ZA201001124B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2706358A3 (en)	2008-12-23	2014-05-07	Merck Patent GmbH	Biomarkers for inhibitors with anti-angiogenic activity
AU2010285265B2 (en)	2009-08-19	2015-05-21	Merck Patent Gmbh	Antibodies for the detection of integrin complexes in FFPE material
MX352025B (es) *	2011-02-11	2017-11-07	Merck Patent Gmbh	Anticuerpo anti-integrina alfa v para el tratamiento de cancer de prostata.
WO2015035215A1 (en) *	2013-09-05	2015-03-12	Amgen Inc.	Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
BR112017005336A2 (pt) *	2014-09-17	2017-12-12	Merck Patent Gmbh	método de tratamento de cânceres sólidos e/ou metástases dos mesmos, medicamentos com essa finalidade e método para prever o resultado clínico de tratamento de cânceres sólidos e/ou metástases dos mesmos
CN106714835A (zh)	2014-09-17	2017-05-24	默克专利股份公司	治疗骨转移疾病的方法、其药物以及预测治疗骨转移疾病的临床结果的方法
HUE050596T2 (hu)	2014-11-21	2020-12-28	Bristol Myers Squibb Co	Antitestek CD73 ellen és azok felhasználásai
LT3221346T (lt)	2014-11-21	2020-11-10	Bristol-Myers Squibb Company	Antikūnai, apimantys modifikuotas sunkiosios grandinės pastoviąsias sritis
US20190144547A1 (en)	2015-11-23	2019-05-16	Merck Patent Gmbh	Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders
AU2016360661B2 (en) *	2015-11-23	2023-12-14	Merck Patent Gmbh	Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders
EP3510407A1 (en)	2016-09-08	2019-07-17	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for diagnosing and treating nephrotic syndrome
CA3046489A1 (en)	2016-12-07	2018-06-14	Progenity Inc.	Gastrointestinal tract detection methods, devices and systems
CA3045931A1 (en)	2016-12-14	2018-06-21	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
AU2018214208A1 (en)	2017-02-02	2019-07-11	Merck Patent Gmbh	Preferred pairing of antibody domains
CN108948206B (zh) *	2017-05-23	2022-08-23	赵磊	一种抗egfr/pd-1双靶向抗体、其制备方法及用途
JP7543134B2 (ja)	2017-10-03	2024-09-02	メルクパテントゲゼルシャフトミットベシュレンクテルハフツング	システイン操作された抗原結合分子
WO2019089544A1 (en) *	2017-11-01	2019-05-09	Tufts Medical Center, Inc.	Bispecific antibody constructs and methods of use
US20230033021A1 (en)	2018-06-20	2023-02-02	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
WO2020079209A1 (en)	2018-10-19	2020-04-23	Merck Patent Gmbh	Abituzumab for the treatment of colorectal cancer
CN116726361A (zh)	2018-11-19	2023-09-12	比奥拉治疗股份有限公司	用生物治疗剂治疗疾病的方法和装置
WO2021119482A1 (en)	2019-12-13	2021-06-17	Progenity, Inc.	Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CN114366749B (zh) *	2020-10-15	2023-06-30	中国人民解放军海军军医大学	整合素抑制剂在制备治疗肾癌的药物中的用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR100240308B1 (ko)	1991-03-06	2000-01-15	플레믹 크리스티안	인간화된단클론성항체및혼성단클론성항체
DK0719859T3 (da) *	1994-12-20	2003-10-20	Merck Patent Gmbh	Anti-alfa V-integrin monoklonalt antistof
JP3461945B2 (ja)	1994-12-26	2003-10-27	株式会社日本製鋼所	高低圧一体型タービンロータの製造方法
DE19534177A1 (de)	1995-09-15	1997-03-20	Merck Patent Gmbh	Cyclische Adhäsionsinhibitoren
DE69833755T2 (de)	1997-05-21	2006-12-28	Biovation Ltd.	Verfahren zur herstellung von nicht-immunogenen proteinen
DE19842415A1 (de)	1998-09-16	2000-03-23	Merck Patent Gmbh	Pharmazeutische Zubereitung
AU776910B2 (en)	1998-12-08	2004-09-23	Merck Patent Gesellschaft Mit Beschrankter Haftung	Modifying protein immunogenicity
WO2002069232A2 (en)	2001-02-19	2002-09-06	Merck Patent Gmbh	Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
AU2003298783B2 (en) *	2002-11-26	2010-11-04	Abbvie Biotherapeutics Inc.	Chimeric and humanized antibodies to alpha5beta1 integrin that modulate angiogenesis
US8147832B2 (en) *	2003-08-14	2012-04-03	Merck Patent Gmbh	CD20-binding polypeptide compositions and methods
KR20060002667A (ko)	2004-07-03	2006-01-09	삼성전자주식회사	디스크 댐퍼와 디스크 프로텍터를 구비한 하드 디스크드라이브
CA2635623C (en) *	2005-12-30	2015-02-17	Michael Super	Anti-cd19 antibodies with reduced immunogenicity
WO2007084620A2 (en)	2006-01-19	2007-07-26	Bassler G Scott	Rapid food chiller

2008
- 2008-07-17 ES ES08784834T patent/ES2395799T3/es active Active
- 2008-07-17 PT PT87848347T patent/PT2167128E/pt unknown
- 2008-07-17 CA CA2693863A patent/CA2693863C/en active Active
- 2008-07-17 US US12/669,408 patent/US8562986B2/en not_active Expired - Fee Related
- 2008-07-17 JP JP2010516422A patent/JP5341889B2/ja not_active Expired - Fee Related
- 2008-07-17 DK DK08784834.7T patent/DK2167128T3/da active
- 2008-07-17 EP EP08784834A patent/EP2167128B1/en active Active
- 2008-07-17 BR BRPI0815567A patent/BRPI0815567B8/pt active IP Right Grant
- 2008-07-17 EA EA201070150A patent/EA019485B1/ru not_active IP Right Cessation
- 2008-07-17 SI SI200830845T patent/SI2167128T1/sl unknown
- 2008-07-17 CN CN200880024003.1A patent/CN101687039B/zh not_active Expired - Fee Related
- 2008-07-17 EP EP12004296A patent/EP2526967A1/en not_active Withdrawn
- 2008-07-17 AU AU2008277907A patent/AU2008277907B2/en not_active Ceased
- 2008-07-17 WO PCT/EP2008/005852 patent/WO2009010290A2/en not_active Ceased
- 2008-07-17 HR HRP20120949AT patent/HRP20120949T1/hr unknown
- 2008-07-17 KR KR1020107003397A patent/KR101559596B1/ko not_active Expired - Fee Related
- 2008-07-17 PL PL08784834T patent/PL2167128T3/pl unknown
2010
- 2010-01-12 IL IL203269A patent/IL203269A/en active IP Right Grant
- 2010-02-16 ZA ZA2010/01124A patent/ZA201001124B/en unknown
2012
- 2012-12-21 CY CY20121101248T patent/CY1113493T1/el unknown

Also Published As

Publication number	Publication date
DK2167128T3 (da)	2012-12-03
CA2693863A1 (en)	2009-01-22
CY1113493T1 (el)	2016-06-22
EP2167128A2 (en)	2010-03-31
US8562986B2 (en)	2013-10-22
HRP20120949T1 (en)	2012-12-31
CN101687039B (zh)	2014-04-16
WO2009010290A2 (en)	2009-01-22
EP2526967A1 (en)	2012-11-28
AU2008277907A1 (en)	2009-01-22
BRPI0815567B1 (pt)	2019-06-04
EP2167128B1 (en)	2012-10-24
PL2167128T3 (pl)	2013-03-29
KR20100057010A (ko)	2010-05-28
EA201070150A1 (ru)	2010-08-30
AU2008277907B2 (en)	2013-08-22
CA2693863C (en)	2017-10-03
WO2009010290A3 (en)	2009-04-09
KR101559596B1 (ko)	2015-10-12
JP2010533480A (ja)	2010-10-28
SI2167128T1 (sl)	2013-01-31
CN101687039A (zh)	2010-03-31
ZA201001124B (en)	2010-11-24
PT2167128E (pt)	2013-01-24
ES2395799T3 (es)	2013-02-15
EA019485B1 (ru)	2014-04-30
JP5341889B2 (ja)	2013-11-13
IL203269A (en)	2014-11-30
BRPI0815567B8 (pt)	2021-05-25
HK1143523A1 (en)	2011-01-07
US20100254977A1 (en)	2010-10-07

Legal Events

Date	Code	Title	Description
2017-03-28	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2017-11-21	B65X	Notification of requirement for priority examination of patent application
2017-12-12	B65Y	Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117)
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-07-31	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2018-11-06	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2019-04-30	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2019-06-04	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/06/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/06/2019, OBSERVADAS AS CONDICOES LEGAIS
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/07/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

Publication	Publication Date	Title
CY2019004I2 (el)	2019-11-27	Τροποποιημενα αντισωματα αντι-ιl-23ρ19
BRPI0815567A2 (pt)	2015-02-18	Anticorpos híbridos antialfa v-integrina projetados
IL212175B (en)	2019-08-29	Muc1* antibodies
BRPI0906877A2 (pt)	2015-07-28	Anticorpos anti-trkb aperfeiçoados
HRP20171011T1 (hr)	2017-09-22	ANTI-eMET ANTITIJELO
BRPI0907237A2 (pt)	2015-07-14	Anticorpo anti-cldn6
EP2337798A4 (en)	2012-10-24	SPECIFIC ANTIBODIES OF THE ASB
BRPI0807895A2 (pt)	2014-06-17	Veículo híbrido
EP2196370A4 (en)	2011-06-01	Hybrid vehicle
EP2211903A4 (en)	2011-07-06	CLL-1 ANTIBODY
DE602008000562D1 (de)	2010-03-11	Fahrzeugrad
BRPI0811014A2 (pt)	2015-01-27	Veículo
BRPI0917148A2 (pt)	2015-12-01	anticorpos anti-cd5
EP2128012A4 (en)	2012-04-11	VEHICLE
EP2177425A4 (en)	2014-06-18	Vehicle
BRPI0807991A2 (pt)	2014-06-17	Anticorpos anti-il-23r elaborados.
EP2172483A4 (en)	2010-08-04	ANTI-MUC17 ANTIBODY
BRPI0909633A2 (pt)	2015-09-22	anticorpos anti-tyrp1
DE602008001297D1 (de)	2010-07-01	Fahrzeugrad
BRPI0817427A2 (pt)	2015-06-16	Anticorpo anti-bst2
DE112008002581A5 (de)	2010-06-24	Antriebsstrang
DK2132234T3 (da)	2013-08-26	Acceleratoropløsning
DE112007003038A5 (de)	2009-09-17	Antriebsstrang
EP2212431A4 (en)	2011-05-11	ANTIBODY AGAINST IREM-1
DE602008000034D1 (de)	2009-08-13	Rollerartiges Fahrzeug